Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System"

Takara Bio Inc. (Takara Bio), announced today that a NY-ESO-1・siTCR gene therapy product (Development code: TBI-1301) for synovial sarcoma co-developed by Takara Bio and Otsuka Pharmaceutical Co., Ltd, (Otsuka) in Japan has been approved for the description change of product under SAKIGAKE Designation System (hereinafter, "SAKIGAKE") by the Ministry of Health, Labour and Welfare as of February 14, 2019.TM Takara Bio is conducting domestic Phase I/II clinical trial of TBI-1301 targeting synovial sarcoma since January 2017, and it has been designated as a SAKIGAKE product in March 2018. This designation change is based on the agreement that Takara Bio has concluded with Otsuka for domestic co-development and exclusive sales in April 2018. Both companies will aim cooperatively for co-development of this product. Description Change Designation Time Number Designation Date Product Name Designated Applicant Designated Efficacy of NY-ESO-1・siTCR gene therapy productTM Before 3 timerd 1 March 27, 2018 TBI-1301 Takara Bio Anti-tumor therapy for synovial sarcoma, which a receptor gene recognizing tumor antigen, is transduced ex-vivo to lymphocytes of patients, and the gene-modified lymphocytes are infused back to the patients After Same as above Same as above Same as above Same as above Otsuka Same as above Reference Announcement on product designation of NY-ESO-1・siTCR gene therapy product for synovial sarcoma under "SAKIGAKE Designation System" by the Ministry of Health, Labour and Welfare (Released on March 27, 2018) http://ir.takara-bio.co.jp/en/news_all/news_Release/news_Release04062404159330868269856.html Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies (Released on April 9, 2018) https://www.otsuka.co.jp/en/company/newsreleases/2018/20180409_1.html

The release as fetched from its publisher. otsuka.co.jp ↗